Quick Answer
Estrella Immunopharma, Inc. reported Net Income of -$13.06 million for fiscal year 2025.
Estrella Immunopharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$13.06M -78.7% |
-$7.31M +34.2% |
-$11.11M -1015.8% |
-$996.1K -302.1% |
-$247.7K | — |
| Diluted EPS | -$0.35 -29.6% |
-$0.27 +99.3% |
-$36.35 | — | — | — |
| Total Assets | $3.18M -28.7% |
$4.45M +47.1% |
$3.03M -68.9% |
$9.72M -78.8% |
$45.80M | — |
| Cash and Equivalents | $1.38M -66.8% |
$4.17M +68.0% |
$2.48M +5976.0% |
$40.8K -91.5% |
$478.9K | — |
| Stockholders Equity | -$10.37M -342.6% |
$4.27M +136.4% |
-$11.74M -1029.3% |
-$1.04M -3.3% |
-$1.01M | $0.00 |
| R&D Expense | $10.25M +149.4% |
$4.11M -60.7% |
$10.45M | — | — | — |
| Operating Income | -$13.06M -78.7% |
-$7.31M +34.2% |
-$11.11M -608.1% |
-$1.57M -530.0% |
-$249.1K | — |
| Shares Outstanding | — | 36.61M +3642.5% |
978,243 -31.1% |
1.42M +0.0% |
1.42M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.80M | -42.2% | +13.4% |
| Diluted EPS | September 30, 2025 | -$0.13 | -44.4% | +13.3% |
| Total Assets | September 30, 2025 | $3.52M | -5.7% | +18.2% |
| Cash and Equivalents | September 30, 2025 | $1.63M | -9.5% | +23.5% |
| Stockholders Equity | September 30, 2025 | -$9.84M | -1418.1% | -61.4% |
| R&D Expense | September 30, 2025 | $4.15M | +46.9% | -10.9% |
| Operating Income | September 30, 2025 | -$4.80M | -42.2% | +13.4% |
| Shares Outstanding | March 31, 2024 | 36.54M | +2473.5% | +3.8% |
- Estrella Immunopharma, Inc. reported Net Income of -$13.06 million for fiscal year 2025.
- Estrella Immunopharma, Inc. showed a decrease of -78.7% in Net Income compared to the prior fiscal year.
- Estrella Immunopharma, Inc. reported Diluted EPS of $0.35 per share (loss) for fiscal year 2025.
- Estrella Immunopharma, Inc. showed a decrease of -29.6% in Diluted EPS compared to the prior fiscal year.
- Estrella Immunopharma, Inc. reported Total Assets of $3.18 million for fiscal year 2025.
- Estrella Immunopharma, Inc. showed an increase of +1.2% in Total Assets compared to the prior fiscal year.
- Estrella Immunopharma, Inc. reported Cash and Equivalents of $1.38 million for fiscal year 2025.
- Estrella Immunopharma, Inc. showed an increase of +51.0% in Cash and Equivalents compared to the prior fiscal year.
- Estrella Immunopharma, Inc. reported Stockholders Equity of -$10.37 million for fiscal year 2025.
- Estrella Immunopharma, Inc. showed a decrease of -7312.1% in Stockholders Equity compared to the prior fiscal year.
- Estrella Immunopharma, Inc. reported R&D Expense of $10.25 million for fiscal year 2025.
- Estrella Immunopharma, Inc. showed an increase of +149.4% in R&D Expense compared to the prior fiscal year.
- Estrella Immunopharma, Inc. reported Operating Income of -$13.06 million for fiscal year 2025.
- Estrella Immunopharma, Inc. showed a decrease of -78.7% in Operating Income compared to the prior fiscal year.
- Estrella Immunopharma, Inc. reported Shares Outstanding of 36.61 million shares for fiscal year 2024.
- Estrella Immunopharma, Inc. showed an increase of +3642.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: